CYTK: Financial results

Item 2.02 Results of Operations and Financial Condition. On November 4, 2026, Cytokinetics, Incorporated announced its financial results for the third quarter ended September 30, 2026. The full text of the press release issued in connection with this announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information furnished under this Item 2.02 and under Exhibit 99.1 shall not be considered “filed” under the Securities Exchange Act of 1934, as amended, nor shall it be incorporated by reference into any future filing under the Securities Act of 1933, as amended, or under the Securities Exchange Act of 1934, as amended, unless the Registrant expressly sets forth in such future filing that such information is to be considered “filed” or incorporated by reference therein. Item 9.01 Financial Statements and Exhibits. (d) Exhibits 99.1 Press Release dated November 4, 2026 104 The cover page of this report has been formatted in Inline XBRL SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. CYTOKINETICS, INCORPORATED Date: November 4, 2026 By: /s/ John O. Faurescu John O. Faurescu, Esq. SVP, Deputy General Counsel & Secretary